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Abstract
Background: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular
edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex
represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the
implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by
mobilization and subsequent balanced saline solution injection in the anterior chamber.
Case presentation: An 83-year-old white woman presented to our Emergency Unit complaining of pain and vision
loss in herright eye lasting a week. Her anamnesis revealed a history of persistent cystoid macular edema after
phacoemulsification with scleral-fixated posterior chamber intraocular lens implantation, recently treated with an
intravitreal Ozurdex implant. She also took a long-distance flight 2 days after the injection.
An anterior segment examination showed corneal edema and the rod implant adherent to corneal endothelium.
To avoid corneal decompensation, we opted for a implant repositioning. Under topical anesthesia, a 30-gauge
needle was introduced through a limbar incisionto mobilize the dislocated rod. Balanced saline solution was
injected, with a successful repositioning of the implant into the vitreous cavity. Topical 5 % hypertonic saline
solution and 0.2 % betamethasone associated with 0.5 % chloramphenicol drops were administered four times a
day. To prevent redislocation of the Ozurdex implant, she was instructed to avoid prone position, any kind of
physical effort, and not to undertake long-distance flights during the first postoperative week. One week after
surgery, an anterior segment examination showed an improvement of corneal edema. Funduscopy showed that
the Ozurdex implant was settled into the vitreous cavity.
Conclusions: Anterior chamber dislocation of Ozurdex from the vitreous cavity is rare. In our patient, in addition to
the posterior capsule tearing, the long-distance flight could have contributed to implant dislocation. Repositioning
of the implant is necessary to avoid endothelial decompensation. It can be carried out by using saline balanced
solution with the same efficacy as other surgical procedures reported in the literature. A possible disadvantage of
this procedure could be implant migration.
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Background
Ozurdex (Allergan Inc., Irvine, CA, USA) is a dexa-
methasone (700 mcg) rod-shaped biodegradable implant
of 6 mm in length and 0.46 mm in diameter, which is
injected by a 22-gauge needle into the vitreous cavity.
The Ozurdex (dexamethasone) intravitreal implant has
been approved to manage several ocular diseases including
macular edema due to retinal vein occlusion [1, 2], nonin-
fectious uveitis affecting the posterior segment [3, 4], and
diabetic macular edema [5]. The efficacy and safety of the
Ozurdex (dexamethasone) implant has been reported in
the literature, including cases of Irvine-Gass syndrome [6].
Despite this evidence, rare complications associated to
the Ozurdex (dexamethasone) implant have been de-
scribed. These include not only long-term adverse events
in cases of required repeated dexamethasone 0.7 mg injec-
tions, such as cataract development and secondary glau-
coma [7], but also complications due to the implant itself,
such as desegmentation (fracture) of the implant [8], acci-
dental injection of Ozurdex (dexamethasone) into the
crystalline lens [9], and migration of the Ozurdex (dexa-
methasone) implant into the anterior chamber [10].
Anterior chamber dislocation of an Ozurdex (dexa-
methasone) implant represents an uncommon complica-
tion of this procedure, which can be managed by extracting
the implant from a sclerocorneal incision or repositioning
to the vitreous cavity [10, 11]. We describe the case of an
efficient repositioning of an Ozurdex (dexamethasone) im-
plant by mobilization and subsequent balanced saline solu-
tion injection in the anterior chamber.
Case presentation
An 83-year-old white woman presented to our Emer-
gency Unit with pain and vision loss in her right eye for
the past week. Her anamnesis revealed a history of per-
sistent cystoid macular edema after phacoemulsification
with scleral-fixated posterior chamber intraocular lens
implantation in her right eye, previously managed by an
intravitreal injection of Ozurdex (dexamethasone); in
addition, her left eye was operated on due to cataracts
without complications. She also informed us of a long-
distance flight she took from Italy to Australia 2 days
after the intravitreal injection.
Anterior segment examination of her right eye showed
conjunctival injection, corneal edema, and the rod implant
dislocated in the anterior chamber, adherent to corneal
endothelium (Fig. 1). The intraocular pressure during the
first visit measured 11 mmHg. After the repositioning of
the dexamethasone implant and throughout her follow-up
visit, her intraocular pressure never exceeded 17 mmHg
in our case study. The dexamethasone implant not only
decreased her macular edema but also helped to improve
her visual acuity. Her best spectacle corrected visual acuity
(BSCVA) was 1.69 LogMAR.
After evaluation of her clinical condition and of the
high risk of corneal endothelial decompensation due to
the toxic action of the rod, we decided to remove it from
the anterior chamber. The surgery was performed at our
Department of Sense Organs. Informed consent was
obtained from our patient. The study adhered to the
tenets of the Declaration of Helsinki for research in-
volving humans.
Clinical intervention was performed under sterile con-
ditions in the operating room. The repositioning of the
intravitreal dexamethasone implant was performed
under sterile conditions and after preparation of her
conjunctiva using 5 % povidone-iodine solution. Under
topical anesthesia with ropivacaine and positioning of
the blepharostat, a limbar incision was made and a
viscoelastic substance was inserted into the anterior
chamber to avoid damaging adjacent structures. A 30-
gauge needle was introduced to mobilize the dislocated
rod. Then, balanced saline solution was injected and a
successful repositioning of the implant in the vitreous
cavity was obtained. The viscoelastic substance was re-
moved from the anterior chamber.
After the repositioning of the dexamethasone implant,
our patient was administered an eye drop formula consist-
ing of 5 % hypertonic solution to reduce the edema of her
cornea for 3 months, 3 times per day. This was combined
with 0.2 % betamethasone associated with a 0.5 % chlor-
amphenicol drop therapy that was administered in de-
scending doses: in the first week four drops per day,
second week she administered three drops per day, the
third week the dose consisted of two drops a day, and later
it was tapered during her postoperative period.
One week after surgery, she did not complain of more
pain and reported an improvement in visual acuity. Her
BSCVA was 1 LogMAR. A fundus examination showed
Fig. 1 Slit-lamp biomicroscopy showing the dexamethasone implant
dislocated in the anterior chamber. The implant is located just in
front of the iris, in the lower part of the visual axis
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that the Ozurdex (dexamethasone) implant was settled
in the vitreous cavity (Fig. 2).
A clinical biomicroscopy examination showed absence
of inflammatory reaction, partial improvement of cor-
neal edema, and the anterior chamber optically empty.
Ethics approval for the procedure described was ob-
tained from our local committee.
Discussion
Anterior chamber dislocation of an Ozurdex (dexa-
methasone) implant from the vitreous cavity is a rare
complication which occurs more frequently in aphakic
eyes or in cases of tear of lens capsule and prior vitrec-
tomy [10]. In addition, unusual body postures, such as
face down or prone positions, can also be a risk factor
for anterior dislocation [12]. To prevent dislocation, the
patients must be instructed not only to avoid a prone
position or physical efforts, but also not to undertake
long-distance flights during the first weeks after Ozurdex
(dexamethasone) intravitreal implant. Once the airplane
has taken off, to ensure the safety of passengers within
the cabin, air pressure is reduced. Due to the decreased
air pressure within the cabin, our internal pressure can
rise within our body cavities causing major complica-
tions in people who have had eye surgery, such as our
patient. The difference in air pressure increased the
pressure of the vitreous with the dexamethasone implant
dislocation in the anterior chamber [13]. In the present
case report, the sudden pressure changes during the
long-distance flight could have contributed to the dis-
location of the implant.
Anterior chamber dislocation of Ozurdex (dexametha-
sone) intravitreal implant can be managed by extracting
the implant from a sclerocorneal incision or reposi-
tioning to the vitreous cavity [6]. Repositioning of the
rod can be managed by different strategies. Although
cases of spontaneous relocation of the implant in the vit-
reous cavity have been reported [14], repositioning of
the implant is necessary to avoid irreversible corneal de-
compensation. Here we describe the case of an efficient
repositioning of an Ozurdex (dexamethasone) implant
by mobilization and subsequent balanced saline solution
injection in the anterior chamber.
The present case report suggests that the efficacy of
mechanical repositioning, carried out using saline bal-
anced solution, can be similar to the efficacy of other
surgical procedures reported in the literature. Mechanical
repositioning has the advantage of minimizing corneal
toxicity and avoids the use of more invasive techniques.
The migration of the dexamethasone implant in the anter-
ior chamber took place 2 days after the intravitreal injec-
tion. The migration persisted for a total of 10 days,
including 2 days necessary for patient’s preparation to the
surgical repositioning of the implant into the vitreous
cavity.
The dexamethasone implant was inserted in her eye in
Italy, before going to Australia for vacation. During her
time in Australia complications arose and it was necessary
for her to visit a hospital. The medical staff in Australia in-
formed her of the seriousness of the problem and requested
surgery. She opted to return to Italy for her surgery as she
felt more comfortable with Italian physicians.
This study is in line with other studies showing that
mechanical repositioning may reduce the need for surgi-
cal intervention. It has been shown that repositioning of
the implant can be achieved with the use of a 30-gauge
needle under topical anesthesia at the slit lamp [15] or
with the patient posturing to reposition the dexametha-
sone implant back into the vitreous cavity [16–18]. Des-
pite this evidence, the choice of the technique adopted
should depend on the location and positioning of the
dexamethasone implant relative to other intraocular struc-
tures. Thus, surgical procedures are sometimes inevitable
to relocate the implant and to manage corneal decompen-
sation and elevated intraocular pressure [19, 20].
Conclusions
In conclusion, this case report indicates that implant re-
positioning can be successfully achieved by mobilization
and subsequent balanced saline solution injection in the
anterior chamber. The procedure is minimally invasive
and, due to its celerity, it can have beneficial effects on
corneal edema caused by an Ozurdex (dexamethasone)
rod in contact with endothelium. However, the disadvan-
tage of this procedure can be the risk for implant migra-
tion. Patients must be instructed not only to avoid a
prone position or physical effort, but also not to under-
take long-distance flights during the first weeks after
Ozurdex (dexamethasone) intravitreal implant.
Fig. 2 Slit-lamp biomicroscopy showing the result of repositioning
of the dexamethasone implant. Corneal edema
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